|
U.S. News Mylan Receives U.S. Approval for HIV/AIDS TreatmentSeptember 22, 2011 Canonsburg, Pa.-based Mylan Inc. said Tuesday it has received tentative US approval for a generic version of an HIV treatment regimen. Included in the regimen are generic versions of GlaxoSmithKline PLC's Epivir (lamivudine), Gilead Sciences Inc.'s Viread (tenofovir), and Boehringer Ingelheim's Viramune (nevirapine). Mylan said its subsidiary, Matrix Laboratories Ltd., received clearance from the Food and Drug Administration through the President's Emergency Plan for AIDS Relief. Eligible for sale outside the United States, the regimen will be offered in some developing nations. Associated Press 09.20.2011 This article was provided by U.S. Centers for Disease Control and Prevention. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update. Visit the CDC's website to find out more about their activities, publications and services.
Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before adding your comment, please read TheBody.com's Comment Policy.) |
|